-
Study aim
-
Achieving fasting blood sugar is 70-130 mg/dl and BS ≤ 160 mg/dl.
-
Design
-
The study is a double blind prospective clinical trial. The number of 128 patients (150 patients including 20% dropout) were randomly divided into two groups of 64 people.
-
Settings and conduct
-
The clinical trial is conducted in the clinic of Shahid Labafinejad Hospital and on type 2 diabetic patients.. On the first day of the study and before the start of the first dose of the drug, fasting blood samples were taken from the patients and the investigated items included FBS, BS, HbA1c, LDL, HDL, Chol, TG, AST, ALT, weight, blood pressure and abdominal circumference of patients are recorded. Also, after 30, 60 and 90 days from the start of the study, these items are re-evaluated. The medicine and placebo are delivered to the nurse in similar packages and the nurse provides them to the patients without knowing the contents of the package, the nurse and the patients will not know about the contents of the package.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: Patients over 18 years old. Having type 2 diabetes. Take oral medicine. HbA1C is more than 7 and less than 10
Exclusion criteria: Patients below 18 years old. Dissatisfaction. Insulin consuming. HbA1C is less than 7 and more than 10
-
Intervention groups
-
After obtaining informed consent, the patients were randomly divided into two groups and one group was treated with placebo and the other group was treated with thyme capsules. Patients take 3 placebo capsules or three thyme capsules daily for up to 3 months along with their other medications.
-
Main outcome variables
-
FBS(Fast blood sugar),HbA1C